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The pathogenesis of hepatocellular carcinoma (HCC) is not fully understood, which has affected the early diagnosis
and treatment of HCC and the survival time of patients. MicroRNAs (miRNAs) are a class of evolutionarily conserved
small, non-coding RNAs, which regulate the expression of various genes post-transcriptionally. Emerging evidence
indicates that the key enzymes involved in the miRNA biosynthesis pathway and some tumor-specific miRNAs are
widely deregulated or upregulated in HCC and closely associated with the occurrence and development of various
cancers, including HCC. Early studies have shown that miRNAs have critical roles in HCC progression by targeting
many critical protein-coding genes, thereby contributing to the promotion of cell proliferation; the avoidance of
apoptosis, inducing via angiogenesis; and the activation of invasion and metastasis pathways. Experimental data
indicate that discovery of increasing numbers of aberrantly expressed miRNAs has opened up a new field for
investigating the molecular mechanism of HCC progression. In this review, we describe the current knowledge
about the roles and validated targets of miRNAs in the above pathways that are known to be hallmarks of HCC,
and we also describe the influence of genetic variations in miRNA biosynthesis and genes.
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Hepatocellular carcinoma (HCC) is the fifth most com-
monly diagnosed cancer worldwide but the third leading
cause of cancer-related death around the world. More-
over, the incidence of HCC is over 50 million every year
[1]. Studies have gradually elucidated the pathogenesis
of HCC in recent years. However, the early diagnosis
and treatment of HCC in clinics are still quite challen-
ging. Epidemiologic studies indicate that the major risk
factor for HCC is chronic hepatitis virus infections,
mainly the hepatitis B virus (HBV) and the hepatitis C
virus (HCV); other risk factors include exposure to cer-
tain chemicals, intake of large amounts of alcohol, some
inherited metabolic diseases and similar factors [2]. Al-
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stood. In terms of disease processes, HCC develops from
chronic diffuse liver disease and cirrhosis. Recent re-
search developments on the underlying pathogenesis of
HCC indicate that its incidence is mainly caused by re-
peated repair and regeneration, inflammation and oxida-
tive DNA damage to liver cells [3]. Of these, the
mechanism by which microRNAs (miRNAs) regulate
HCC development has recently become a focus of re-
search in molecular biology. Increasing evidence indi-
cates that miRNAs are expected to become new
diagnostic markers and therapeutic targets of HCC.
miRNAs are small, evolutionarily conserved, single-
stranded RNA molecules that are approximately 21–24
nucleotides in length. miRNAs regulate gene expression
by binding to specific mRNA targets and promoting
their degradation and/or translational inhibition [4]. As
regulators of gene expression, miRNAs fine-tune a var-
iety of essential cellular processes, including cell growth,
differentiation, metabolism and apoptosis [5]. The vast
majority of miRNAs can bind to their target mRNAs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tumor formation, miRNAs can play roles of oncogenes
or tumor suppressor genes because of the combination
of different target mRNAs. Abnormal activation and in-
activation of oncogenes and tumor suppressor genes are
important factors leading to malignancy (including
HCC). Clarifying the molecular mechanisms of HCC
could provide a basis for HCC risk assessment, early
diagnosis, effective treatment and intervention. In this
review, we will summarize the influence of the abnormal
biosynthesis of miRNAs and the aberrant expression of
miRNAs on the cell cycle of tumor cells, angiogenesis,
the activation of invasion and metastasis and the occur-
rence and development of HCC. Understanding the mo-
lecular pathogenesis of HCC can provide evidence for
assessing predisposing factors, early diagnosis, treatment
and intervention for HCC.
The basics of miRNA biogenesis
The synthesis of miRNA mainly consists of two steps, in-
cluding nuclear synthesis within and outside the nucleus.
First, RNA polymerase II acts on the miRNA coding re-
gion in the nucleus, and the coding region is transcribed
to primary miRNA (pri-miRNA) that contains hundreds
of thousands of nucleotides. Subsequently, pri-miRNAs
are processed to an miRNA precursor (pre-miRNA) in the
nucleus by the microprocessor complex, which consists of
the nuclease Drosha and DiGeorge syndrome critical re-
gion gene 8 (DGCR8). Pre-miRNAs are approximately 60
to 70 nucleotides in length with a stem-loop structure [7].
Then, pre-miRNAs are transported to the outside of the
nucleus with the help of the RAS-related nuclear protein
with bound GTP (RAN-GTP)-dependent transporter
exportin-5 (XPO-5). Pre-miRNAs are released from the
Drosha-DGCR8 microprocessor complex in the nucleus,
which has a high concentration of RAN-GTP, and are
transferred to the cytoplasm along with XPO-5. Pre-
miRNAs are released in the cytoplasm, where the concen-
tration of RAN-GTP is low. In the cytoplasm, pre-
miRNAs undergo additional cleavage by the RNase III
endoribonuclease Dicer. The result of this process is the
formation of an incomplete matching duplex approxi-
mately 21 to 24 nucleotides in length composed of the
mature miRNA, which is consequently connected to the
RNA-induced silencing complex (RISC) and miRNA*,
which is degraded after separation from the complex [8].
Finally, with the help of helicases such as Gemin3 or
RCK/p54, mature single-stranded miRNAs are generated.
The TAR RNA binding protein or TARBP2 (TRBP), Argo-
naute 2 (Ago2) and Dicer are involved in the formation of
the RISC loading complex (RLC), which can facilitate the
binding of the mature miRNA to RISC, where it mediates
gene silencing either by translational inhibition or by pro-
moting the degradation of target mRNAs [9]. RISCrecognizes the target mRNA by imperfect pairing with
mRNA 3’ untranslated regions (3’UTR) and perfect
pairing with the target mRNA. This recognition results in
mRNA degradation and thus the degradation or transla-
tion inhibition of the target genes [10]. Gemin4 is one of
important components that contributes to both miRNA
processing and target gene silencing [11].
Role of the aberrant expression of key enzymes involved
in the miRNA biosynthesis pathway in the occurrence and
development of hepatocellular carcinoma
As the key upstream regulatory factors of miRNAs, the
key enzymes involved in the miRNA biosynthesis path-
way include Drosha, DGCR8, XPO-5, RAN, Dicer, TRBP,
AGO1, AGO2, Gemin4 and Gemin3. The aberrant ex-
pression of these enzymes can change a series of down-
stream miRNAs and factors, which promote or inhibit
tumors to interact with each other. Next, the role of
some key enzymes in the miRNA biosynthesis pathway
and their abnormal expression will be introduced in the
occurrence and development of hepatocellular carcin-
oma (Figure 1).
Aberrant key enzymes involved in the regulation of the
processing step from pri-miRNA to pre-miRNA
Research indicates that Drosha and DGCR8 are the key
enzymes involved in the regulation of the processing step
from pri-miRNA to pre-miRNA in many types of tumor
cells. However, the pri-miRNA to pre-miRNA processing
of some miRNAs is relatively independent of the complex
of purified DGCR8 and Drosha [12]. Drosha and DGCR8
are frequently over-expressed in HCC. Angela M. Liu and
colleagues recently showed that of the genes involved in
the biosynthesis of miRNAs, DROSHA is the most differ-
entially expressed in HBV-associated HCC [13]. Moreover,
aberrant expression of Drosha can be observed in ovarian
cancer, cervical cancer and breast cancer, suggesting that
Drosha is involved in many tumors [14]. In addition, the
activity of Drosha can be inhibited by HBV. Min Ren and
colleagues found that HBV could inhibit the promoter ac-
tivity of Drosha via HBx and thereby could downregulate
Drosha expression; the transcription factors SP1 and AP-
2a might assist in this downregulation [15].
Aberrant key enzymes involved in controlling the nuclear
export of pre-miRNA
The nuclear export of pre-miRNAs mostly relies on
XPO-5, whose damage in tumor cells may result in glo-
bal downregulation of mature miRNAs. Pre-miRNAs are
retained in the nucleus in various types of human can-
cer; thus, a gene defect in the nuclear transporter of pre-
miRNAs may be associated with the occurrence of hu-
man tumors [16]. XPO5-inactivating mutations are al-
ways observed in many human tumors, indicating that
Figure 1 Schematic representation of the biogenesis pathway of microRNAs and the aberrant expression of key enzymes involved in
this pathway in HCC. First, miRNAs are transcribed by RNA pol II/III from the miRNA coding gene to pri-miRNAs, and soon afterwards
microprocessor complex recognizes pri-miRNA to generate pre-miRNA. XPO-5 with its cofactor RAN-GTP mediates the nuclear export of
pre-miRNA. Finally, the RLC loading complex assists in the binding of mature miRNA to RISC to mediate gene silencing. However, in HCC, the
expression of some key enzymes involved in this pathway appears to be aberrant, and this aberrant expression results in an abnormal microRNA
biogenesis pathway (shown in A/B/C/D/E).
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gene [17]. During cell cycle entry, the general elevation
of miRNAs is important for controlling gene expression.
Yuka W and colleagues showed that XPO5 is induced by
a PI3K-dependent post-transcriptional mechanism and
that the suppression of XPO5 can interfere with the gen-
eral elevation of miRNA, leading to dysfunctional cell
proliferation related to the G1/S transition. However,
XPO5 is involved in the export of not only pre-miRNAs
but also other non-miRNA molecules [18]. Although re-
search has demonstrated the elevation of primary miR-
NAs that are likely to target key cyclin, there is still
possibility of non-miRNA XPO5 targets of cell cycle
control. Verification of the latter possibility requires fur-
ther study [17].Aberrant key enzymes involved in the regulation of the
processing step from pre-miRNA to mature miRNA
Dicer is responsible for the dicing and maturation of
miRNA. Most miRNAs are Dicer dependent. However,
some scholars have reported that the dicing and matur-
ation of miR-451 are dependent on Ago2, not Dicer
[19,20]. Dicer is coded by the human Dicerl gene, and
the latter acts as a haplo-insufficiency tumor suppressor
gene [21]. In addition, some studies have demonstrated
that Dicerl is the susceptibility gene of familial pleuro-
pulmonary blastoma by family-based linkage analysis
and gene mutation detection [22], and in a mouse
model, the monoallelic Dicerl-knockout may lead to ret-
inoblastoma [21]. All these findings indicate that Dicerl
mutation can increase tumor susceptibility.
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HCC. The Dicer level is significantly lower in HCC than
in adjacent non-neoplastic tissues [23]. Sekine et al.
found increased expression of growth promotion genes
and the embryonic stage of specific genes in the liver
cells of Dicerl-knockout mice. The Dicer1 knockout led
to both increased hepatocyte proliferation and apoptosis
and a change in blood vessel formation and remodeling
[24,25]. More than 60% of the Dicer1-deficient mice de-
veloped HCC derived from residual Dicer1-deficient he-
patocytes at 1 year of age. These findings demonstrate
that Dicer may play a key role during the process of
hepatocarcinogenesis. Han et al. used the shRNA of
adenoviral vector to silence the expression of Dicer in
tumor cells. They found that the ability of tumor cells to
proliferate and invade greatly improved, which was re-
lated to the activation of the p-AKT gene and the in-
creased expression of cyclin A, PCNA and the invasive
proteins MMP-2 and MMP-9. These results showed
that the downregulation of Dicer in tumor cells can pro-
mote tumor development via an indirect mechanism.
However, the upregulation of Dicer expression still oc-
curs in a handful of tumors. For example, the expression
level of Dicer mRNA in patients with stage 3 colorectal
cancer is higher than those at stage 2 [26]; in bronchoal-
veolar carcinoma and lung adenocarcinoma, Dicer
mRNA is upregulated [27]. Therefore, a low expression
level of Dicer may promote the progress of most tumors
that are characterized by higher malignancy and poorer
prognosis. However, the opposite conclusions have been
reported in the study of colorectal cancer, bronchoalve-
olar carcinoma and lung adenocarcinoma, which sug-
gests that the carcinogenic mechanism of Dicer is
tumor specific. The reason of this radical difference is
unknown.
Another key enzyme involved in the regulation of the
processing step from pre-miRNA to mature miRNA is
Ago2. Over-expression of Ago2 markedly reduces HCC
growth. The function of Ago2 can be adjusted by miRNAs.
For example, the tumor suppressor miRNA let-7 could tar-
get Lin-41, whose function is to regulate the ubiquitylation
and degradation of Ago2; this change thus leads to a high
tumor grade and a high tumor stage. Lin-41 can be a pre-
dictor of early intrahepatic recurrence. Over-expression of
Lin-41 can suppress the expression of the Ago1 and Ago2
of RISC and this suppression can promote the growth of
tumor cells. These findings indicate that Lin-41 leads to
cancer by suppressing RISC [28]. In addition, miR-99a dir-
ectly regulates Ago2 through translational repression in
HCC. Downregulation of miR-199a and upregulation of
Ago2 are also inversely associated in HCC [29]. These stud-
ies provide potential strategies for HCC therapy by regulat-
ing Ago2 to activate RISC or reintroduction of miRNA
suppressors.miRNA and genetic predisposition for HCC
There are genetic differences in the DNA sequences of
various individuals, and the chief difference occurs as a
single-nucleotide polymorphism (SNP). The severity of
disease and the way our body responds to treatment are
also manifestations of genetic variations. Genetic varia-
tions, mostly SNPs within miRNA-processing genes,
miRNA sequences and miRNA-binding sites, have been
found to be associated with various types of cancers.
These three types of SNPs could affect cancer risk [30].
In recent years, increasing research has indicated a close
relationship between SNPs in microRNA regulatory
genes and the genetic susceptibility to primary liver can-
cer [31]. SNPs may affect the activity of key enzymes in-
volved in the miRNA biosynthesis pathway. For
example, one group found that the genotypes of CT/CC
in the rs1057035 locus of the DICER gene could de-
crease the risk of HCC significantly while the AG/GG in
the rs3803012 locus of the RAN gene might increase the
risk of HCC. Thus, the combined effects of multi-gene
alleles and multi-locus genotypes might have a synergis-
tic role in the carcinogenesis of liver cancer [32]. In
addition, the genotype of AA in the rs11077 locus of the
XPO5 gene might be genotype susceptible to the worse
survival in HCC patients [33]. These facts indicated that
the SNP of key enzymes involved in the miRNA biosyn-
thesis pathway might play a critical role in tumorigen-
esis. Furthermore, these SNP-related studies must be
verified for HCC. Given the importance of SNP in
miRNA function, SNPs are thought to affect the suscep-
tibility of tumor sequentially. The TC/CC genotypes in
rs4938723 in the promoter region of pri-miR-34b/c were
investigated and shown to be associated with signifi-
cantly increased susceptibility and risks in HCC com-
pared with the wild-type TT patients [34]. However, the
patients with CT and CC genotypes of the rs11614913
SNP in mature miR-196a2 might have altered suscepti-
bility and progression of HCC and also have a higher
risk of developing HCC [35]. Similarly, a study detected
that the rs999885 AG/GG genotypes located in the miR-
106b-25 cluster sequence were apparently associated
with an increased HCC risk compared with that in the
AA genotype carriers [36]. SNPs located at the 3’ un-
translated regions (3’UTR) of genes might modulate the
expression of target genes by influencing the stability
and translation regulation of certain mRNAs. For ex-
ample, in one meta-analysis, the miR-146a*C variant
(rs2910164) and miR-196a-2*T (rs11614913) contained
in the genes encoding miR-146a and miR-196a-2, re-
spectively, were shown to decrease the risk and increase
the susceptibility to HCC, respectively [37]. In summary,
miRNA-related SNPs play a substantial role in cancer
development (Table 1). However, we currently have little
knowledge of the overall contribution of these types of
Table 1 miRNA-related SNPs in hepatocellular carcinoma
SNP Correlation Comparison model and P value
miR-DICER rs1057035 Higher risk CT/CC vs TT,OR = 0.79,95% CI = 0.64-0.96, P < 0.05
miR-RAN rs3803012 Lower risk AG/GG vs AA,OR = 1.35,95% CI = 1.03-1.77, P < 0.05
miR-XPO5 rs11077 Worse survival AA vs AC/CC,OR = 0.395,95% CI = 0.167-0.933, P < 0.05
pri-miR-34b/c rs4938723 Higher susceptibility and risk TC/ CC vs TT,OR = 1.580,95% CI = 1.029-2.426, P < 0.05
miR-196a2 rs11614913 Higher risk CT/CC vs TT,OR = 1.784,95% CI = 1.082-2.944, P < 0.05
miR-106b-25 rs999885 Higher risk AG/GG vs AA,OR = 1.250,95% CI = 1.060-1.470, P < 0.05
miR-146a rs2910164 Lower risk CC vs CG/GG,OR = 0.850,95% CI = 0.760-0.960, P < 0.05
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designed to study the relationship between cancer risks
and miRNAs and their related SNPs in the whole gen-
ome is warranted.
The regulation of miRNAs in HCC
Ten biological capabilities acquired during the multistep
development of human neoplasms form the hallmarks of
cancer [38]. Some of these hallmarks are actually regu-
lated by miRNAs. The expression of aberrant miRNAs
are included in the molecular pathways and biological
functions altered in hepatocarcinogenesis. Furthermore,
miRNAs play essential roles in the cell cycle, apoptosis,
angiogenesis, metastasis and other important processes
[5]. Understanding the biological roles and specific tar-
gets of miRNAs will open up new avenues for investigat-
ing crucial cancer-associated mechanisms in liver.
Deregulated miRNAs involved in the cell cycle
Cell cycle dysregulation is an essential step in the initi-
ation and development of human malignancies, includ-
ing HCC. Accumulating evidence has shown that
deregulated miRNAs may affect HCC cell proliferation
through direct interaction with critical regulators of cell
cycle machinery [39]. Such miRNA targets include cyc-
lin, cyclin-dependent kinases (CDK), cyclin-dependent
kinase inhibitors (CDKI) and other cell growth regula-
tors (Figure 2).
Cyclin D, with the help of CDK4/6, is a crucial medi-
ator of the G1 to S progression. Cyclin D is divided into
3 types, that is, cyclin D1, D2 and D3. The upregulation
of cyclin D1 has been shown to promote the rapid cell
growth of HCC [40]. Many miRNAs that target cyclin
D1 are significantly downregulated in HCC. For ex-
ample, miR-338-3p inhibits tumor cell proliferation and
induces cell cycle arrest at the G1/S checkpoint by
directly targeting cyclin D1 expression in HBV-positive
liver cancer cells [41]. On the one hand, miR-26 dramat-
ically inhibited HCC cell proliferation by inducing G1
arrest [42]. miR-26a could target interleukin-6 (IL-6),
which stimulates the phosphorylation of signal transducer
and activator of transcription 3 (Stat3); subsequently, theexpression of Stat3 target genes, including cyclin D1,
was significantly reduced. Thus, miR-26a might sup-
press the tumor growth of HCC cell through IL-6-Stat3
signaling [43]. On the other hand, miR-26a is also an in-
hibitor of the G1/S transition that directly targets cyclin
D2 and E2 [44]. Moreover, other miRNAs affecting the
expression of cyclin D1 include miR-193b, and miR-195
[45,46]. Apart from the silencing of cyclin D1, miR-195
could also directly target elements that are both up-
stream (such as CDK6) and downstream (such as E2F3)
of Rb, providing new insight into the aberrant Rb-
inactivation frequently found in HCC [45]. In addition,
Cyclin D3, a target of miR-138, was observed to be
negatively associated with miR-138, which was down-
regulated in HCC tissues compared with adjacent non-
tumor tissues [40].
The combination of cyclin B with CKD1 is the crucial
checkpoint for starting the G2/M transition. miR-122 is
a crucial miRNA that indirectly regulates the interaction
of cyclin B and CKD1 to arrest the cell cycle in the G2/
M phase. miR-122 is a highly abundant liver-specific
miRNA and is frequently downregulated in liver cancers.
It functions as a tumor suppressor by directly targeting
several positive regulators of cell cycle progression that
have been implicated in tumorigenesis, including SRF,
Igf1R, ADAM 17, ADAM10, cyclin G1, Wnt1, Bcl-w
and PI3CG [47-51]. As a proto-oncogene, cyclin G1 is
closely related to cancer [52]. Cyclin G1 is over-
expressed in HBV-infected liver cells, where decreased
expression of miRNA-122 is frequently found [51]. Ex-
cessive cyclin G1 in association with PP2A B subunits
promotes the dephosphorylation of Mdm-2, which is a
repressor protein of p53. Then, it could inhibit p53 ubi-
quitination, which accelerates the degradation of p53.
However, p53 decreases the expression of cyclin G1.
This shows a negative feedback. This process is known
to inhibit apoptosis and thus leads to tumors with unre-
stricted growth. Additionally, the increase of miR-122 in
HCC could inhibit cyclin G1 and the cell cycle arrest in
the G2/M phase, which could inhibit the proliferation of
cancer cells [53]. p53 upregulates the expression of p21,
which is known to competitively inhibit cyclin B-CDK1
Figure 2 Deregulated miRNAs in HCC affect cell cycle. These miRNAs impact cell cycle progression by targeting cell growth regulators. The
green miRNAs may promote the HCC cell cycle, and the red miRNAs may inhibit the HCC cell cycle.
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phase. Yanmin Xu et al. also reported that Bcl-W and
cyclin G1 were the targets of miR-122 [54]. In addition,
there are other studies showing that miRNA-122 could
inhibit proliferation in many liver cancer cell lines (such
as HepG2, Hep3B, Huh7 and PLC/PRF/5) [47,55]. In
short, both of these investigations show that miRNA-122
can inhibit hepatocarcinogenesis by directly targeting
cyclin G1.
Remarkably, there are still some miRNAs that act as
oncogenic miRNAs and target negative regulators of the
G1/S transition of the mitotic cell cycle, such as CIP/
KIP family members, and those miRNAs are upregulated
in human HCC and promote the proliferation of HCC
cells. For example, p21Cip1/Waf1 was revealed to be a
downstream target of miR-423-3p, and it is another
miRNA that could notably promote the cell cycle pro-
gression at the G1/S transition in HCC cells [56]. An-
other investigation revealed that CDKN1B/p27 and
CDKN1C/p57 were downregulated in HCC cells as dir-
ect targets of miR-221; the upregulation of miR-221 can
promote cell proliferation and increase the progression
to S phase [57].
Deregulated miRNAs in apoptosis
Apoptosis is a natural barrier to tumorigenesis and
tumor progression. Cancer cells evolve to evade apop-
tosis to escape from the supervision of the body and to
survive in the difficult tumor environment. The Bcl-2
family is composed of a series of pro-apoptotic mem-
bers, such as Bax, Bak, Bid, Bim and Bmf, as well asanti-apoptotic members, such as Bcl-2, Bcl-XL, Bcl-W
and Mcl-1 [58]. After receiving a death signal, the pro-
apoptotic members undergo dephosphorylation and
cleavage, resulting in their activation and translocation
to mitochondria; then, apoptosis is initiated. All BH3-
only proteins require multi-domain BH3 proteins (such
as Bax and Bak) to help them perform their intrinsic
pro-apoptotic activities. These anti-apoptotic members
could bind to and suppress those pro-apoptotic mem-
bers, which could lead to mitochondrial membrane per-
meability changes via the mitochondrion-mediated
apoptotic pathway. This change can keep mitochondria
from releasing a proapoptotic factor, that is, cytochrome
C (cytC), to prevent or delay cell death [58,59]. When
released from mitochondria, cytC in the cytoplasm
forms a complex with Apaf-1 and caspase 9 by way of
cascade amplification and continues to activate caspase
3 and other downstream caspases, eventually leading to
apoptosis [60]. A great majority of deregulated miRNAs
are involved in mitochondrion-mediated apoptosis.
There are many miRNAs that target anti-apoptotic mem-
bers of the Bcl-2 family. Most are significantly downregu-
lated in HCC. For instance, miR-16 and miR-29 are
downregulated in HepG2 cells, and one of their target
genes is confirmed to be Bcl-2 [61,62]. There are some
other miRNAs whose target gene is Mcl-1. Apart from si-
lencing of Bcl-2, miR-29 can also directly target Mcl-1 in
mitochondrion-mediated apoptotic pathway [62]. In
addition, miR-101, miR-193b, miR-125b, and let-7c, which
are downregulated in HCC cells, might exert anti-apoptotic
action via targeting Mcl-1 [63-66]. The downregulation of
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induced apoptosis by directly targeting Mcl-1 and Bcl-w;
miR-125b could also indirectly suppress the levels of Mcl-1
and Bcl-xL by attenuating the IL-6/STAT3 signaling in cell
lines derived from the liver [65]. In addition, let-7c and let-
7g can combine with the 3'-untranslated region of their
target mRNAs, leading to an obvious decrease in the
expression of Bcl-xl, which could lead to anti-apoptotic ten-
dencies [66]. However, miR-122, as a hepato-specific micro-
RNA, was also detected, and it directly targets the binding
site within the 3'-UTR of Bcl-w in HCC cells [67], which
can inhibit the apoptosis of tumor cells.
However, some miRNAs that inhibit apoptosis by target-
ing pro-apoptotic members of the Bcl-2 family are signifi-
cantly upregulated in HCC. For example, the consistent
overexpression of miR-25 promotes cell proliferation in
HCC; miR-25 targets the BH3-only protein Bim [68]. In
addition, miR-221 inhibits apoptosis by targeting the proa-
poptotic BH3-only protein Bmf in HCC [69].
Deregulated miRNAs in angiogenesis
The growth of a solid tumor must rely on continuous and
extensive angiogenesis. Tumor angiogenesis principally re-
lies on vascular endothelial growth factor (VEGF)-driven
angiogenic responses, which lead to a dysfunctional vascu-
lature [70]. Moreover, the invasion of endothelial cells
(ECs) occurs after the release of matrix metalloproteinase
2 and 9 (MMP2/9), which destroy and degrade the basal
membrane and extracellular matrix, finally resulting in the
migration of ECs and the formation of neovessels [71].
Some of these genes involved in angiogenesis have been
reported to be affected by the altered expression of miR-
NAs. The miRNAs involved in angiogenesis mainly target
VEGF and MMP-2/9; furthermore, they are frequently
downregulated in HCC. For instance, Bisheng Zhou and
colleagues demonstrated that the miR-503 downregulation
in HCC plays an anti-angiogenesis role in hepatocarcino-
genesis by targeting VEGF directly [72]. miR-491 and
miR-29b could also target MMP-2/9. For example, the in-
hibition of miR-491 in HepG2 cells increased the expres-
sion of MMP-2/9, which induces angiogenesis [73].
Another study revealed that the inhibition of MMP-2
could phenocopy the anti-angiogenesis and anti-invasion
effects of miR-29b, whereas, the introduction of MMP-2
could attenuate the function of miR-29b in HCC cells
[74]. However, many elements involved in angiogenesis
have not been found to be targets of miRNAs, which
leaves vast spaces for studying.
Deregulated miRNAs in invasion and metastasis
The invasion and metastasis of tumor cells are influ-
enced by the deregulation of components these same
pathways, such as receptor tyrosine kinases (RTKs), and
the downstream phosphatidyl inositol 3-kinase (PI3K)-Akt kinase signaling pathways. Overwhelming evidence
indicates that different miRNAs could regulate the above
pathways (see Figure 3).
Among the downstream effectors of RTK signaling
pathways, Ras has shown over-expression in HCC and
has been regulated by members of the let-7 family.
Moreover, the downregulation of the let-7 family is often
reported in HCC, suggesting a possible contribution to
the upregulation of Ras [75]. Furthermore, miR-125b
can regulate a downstream target, lin-28 homolog B
(LIN28B), in HCC cells, and subsequently indirectly pro-
mote the processing of let-7. Subsequently, Ras is inhib-
ited, which is followed by the inhibition of HCC cell
migration and invasion [76]. However, there are still
some miRNAs that could activate Ras, resulting in the
promotion of HCC cell migration and invasion.
The epithelial-mesenchymal transition (EMT) is crit-
ical for HCC cell migration and invasion, and many
miRNAs have been found to be directly or indirectly as-
sociated with this process [77]. Among them, two
miRNA families, that is, the miR-200 and miR-34 fam-
ilies, are the most important for EMT. E-cadherin is the
key component in EMT. The miR-200 family, which is
upregulated by p53, can target both ZEB1 and ZEB2,
two transcriptional repressors of E-cadherin [78]. An-
other family is the miR-34 family, which directly regu-
lates SNAI1-dependent EMT [79]. miR-34a can also
potently inhibit HCC migration and invasion by directly
targeting c-Met and thereby decreasing the c-Met-
induced phosphorylation of extracellular signal-regulated
kinases 1 and 2 (ERK1/2), suggesting the miR-34a plays
an important role in tumor migration and invasion
[80,81]. Apart from the above families, some miRNAs
can maintain EMT. For example, miR-101 and miR-192
can repress ZEB2 and EZH2 to maintain E-cadherin ex-
pression [78,82]. In addition, there are still other miR-
NAs that regulate the EMT process. For example, miR-
612 has inhibitory effects on HCC migration, invasion
and metastasis with one direct target, AKT2, through
which EMT is inhibited [83]. The Eph tyrosine kinase
receptor (EphA4) is one of target genes of miR-10a; by
specifically targeting EphA4, miR-10a can act on inva-
sion through EMT and on adhesion through the β1-
integrin pathway in HCC cells [84]. ROCK2 (Rho-associ-
ated protein kinase 2, ROCK2) can promote EMT
through a Rho-dependent actin cytoskeleton remodeling
pathway to enhance the invasive and metastatic activity
of HCC, and miR-124 can directly target ROCK2 and
EZH2 genes to inhibit EMT, which leads to inhibition of
the invasive and metastatic activity of HCC [85].
The following additional deregulated miRNAs are in-
volved in the invasive and metastatic properties of HCC
cells. Some of them are significantly upregulated in HCC
and target some key signaling molecules that inhibit
Figure 3 Deregulated miRNAs in invasion and metastasis. The expression of many miRNAs involved in HCC cell invasion and metastasis are
altered and affect RAS-, RHO-, and EMT-related signaling pathways. The green miRNAs may inhibit HCC cell invasion and metastasis, and the red
miRNAs may promote HCC cell invasion and metastasis.
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III domain containing 3B (FNDC3B) regulates cell motil-
ity. In HCC, NF-kappaB can lead to the overexpression
of miR-143, and miR-143 can target FNDC3B, which
could promote HCC invasion and metastasis by improv-
ing cell motility [86]. In addition, miR-21 also plays an
important role in promoting HCC migration and
invasion by targeting programmed cell death 4 (PDCD4)
and simultaneously upregulating downstream signaling
pathway molecules, such as phospho-c-Jun, matrix me-
talloproteinase(MMP)-2 and MMP-9 [87]. Moreover,
miR-550a also promotes HCC cell migration and inva-
sion by targeting cytoplasmic polyadenylation element
binding protein 4 (CPEB4) [88].
However, the decreased expression of many miRNAs
that inhibit the invasion and metastasis of HCC are
often observed in both HCC tissues and cell lines. For
instance, miR-125a, which is always significantly down-
regulated in HCC, inhibits the metastasis of tumor cells
by targeting MMP11 and vascular endothelial growth
factor A (VEGF-A) [89]. Similarly, miR-424, which is
also down-regulated in HCC, suppresses tumor cell mi-
gration and invasion through its downstream target c-Myb [90]. Other key signaling molecules that promote
metastasis of HCC are targeted by miRNAs, including
a disintegrin and metalloprotease 17 (ADAM17), metas-
tasis suppressor 1 (MTSS1), type I collagen alpha2
(COL1A2), and other factors [91-93].
Deregulated miRNAs in PI3K/Akt/mTOR/autophagy
pathway
The phosphoinositide 3-kinase (PI3K) pathway is a very
important signal transduction system that is bound up
with oncogenes and various receptors to regulate many
key cellular functions, such as proliferation, differenti-
ation, migration, trafficking, apoptosis and glucose
homeostasis [94]. The activated PI3K phosphorylates
phosphatidylinositol biphosphate (PIP2) to form phos-
phatidylinositol triphosphatase (PIP3), thus leading to
the phosphorylation and activation of Akt. The most
commonly studied class I PI3K consists of a p110 cata-
lytic subunit and a p85 regulatory subunit. p110 catalytic
subunits are divided into many subunits, such as phos-
phoinositide 3-kinase catalytic subunit alpha (PIK3CA)
and delta (PIK3CD). These catalytic subunits are regu-
lated by miRNAs. For example, the overexpression of
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thermore, miR-7 targets PIK3CD, mTOR, and p70S6K
[96], both of which result in suppression of the PI3K/Akt/
mTOR-signaling pathway. These facts indicate that miR-
NAs could act as tumor regulators by suppressing PI3K to
inhibit the metastasis of HCC.
PTEN can convert PIP3 back to PIP2 and can negatively
regulate the expression of PIP3. By targeting PTEN, miR-
21 and miR-221 show invasive properties. miR-21 regu-
lates various processes that promote tumor invasiveness
by targeting PTEN and PDCD4 in HCC. In addition, miR-
21 could target RECK, which negatively regulates MMP-9,
and lead to increasing invasion [97]. Moreover, PTEN is
one of the target genes of miR-29a and can subsequently
lead to Akt phosphorylation, which regulates the migra-
tion of hepatoma cells [98]. However, the targeting of
PTEN and AKT3 by miR-519d could contribute to hepa-
tocarcinogenesis [99].
HBx has been proven to play a key role in the molecular
pathogenesis of HBV-related HCC and has a close relation-
ship with miRNAs. For example, HBx can repress miR-
148a, and the latter subsequently targets hematopoietic
pre-B cell leukemia transcription factor-interacting protein
(HPIP), which leads to downregulation of AKT and mTOR
through the AKT/ERK/FOXO4/ATF5 pathway [100]. HBx
can also up-regulate the expression of URG11, which sub-
sequently up-regulates β-catenin; PTEN has been shown to
be targeted by miR-148a and thereby contribute to hepato-
carcinogenesis [101]. Another study constructed a lentivirus
vector and performed dual-luciferase reporter assays to
confirm that miR-29a could target SPARC and thereby
both inhibit the phosphorylation of SPARC/AKT/mTOR
and HCC growth [102].
mTORC1 and mTORC2 are two different complexes of
mTOR. AKT activates mTORC1, while mTORC2 acti-
vates AKT. There are many miRNAs that target mTOR.
For example, miR-99a, which was found to be significantly
decreased in HCC, could directly target insulin-like
growth factor 1 receptor (IGF-1R) and mTOR, suggesting
that miR-99a is a promising tumor suppressor for HCC
[103]. Apart from miR-99a, miR-199a-3p also targets
mTOR in HCC cells [97]. In addition, mTOR could also
be regulated by miRNAs indirectly. For example, DNA
damage-inducible transcript 4 (DDIT4), a modulator of
the mTOR pathway, has been identified as a target of
miR-221; thus, miR-221 can regulate the mTOR pathway
indirectly [104].
Activated mTORC1 downregulates autophagy. The
hallmark of autophagy is the transition of LC3-I to its
lipidated form (LC3-II), which requires the help of
autophagy-related-gene 7 (Atg 7) [95]. To date, two
miRNAs were demonstrated to be related to the autoph-
agy process of HCC. One is miR-375, which inhibits au-
tophagy by targeting ATG7 and weakens the viability ofHCC under hypoxic conditions [105,106]. Another one
is miR-199-5p, whose downregulation ensures autophagy
by targeting ATG7. Often, HCC patients have a low level
of miR-199a-5p after treatment with cisplatin-based
chemotherapy. Cisplatin treatment also results in de-
creased miR-199a-5p levels in human HCC cell lines.
miR-199a-5p/autophagy signaling represents a novel
pathway that regulates chemoresistance and thus offers
a new target for the cisplatin-based chemotherapy of
HCC [107].
The insulin receptor substrate1 (IRS1) protein is a key
mediator of insulin-like growth factor (IGF) signaling
which regulates a variety of cellular processes including
growth, differentiation, survival and metabolism. IRS1 is
targeted by miRNA-145 and they are negatively corre-
lated in HCC. Thus, the dysregulation of miR-145 may
contribute to a potential molecular mechanism of car-
cinogenesis in HCC [108].
Conclusions
Ten years of research on this class of tiny non-coding
RNAs has provided significant understanding, confirming
that miRNAs have emerged as novel players in cell
growth, differentiation, proliferation, apoptosis, inflamma-
tion and tumorigenesis. There is sufficient evidence to in-
dicate that the specific expression of miRNAs affects the
occurrence and development of tumors and may be asso-
ciated with pathobiology and clinical features. Moreover,
functional and target connection studies on dysregulated
miRNAs in HCC and their key enzymes have provided us
a more comprehensive understanding of their roles in
oncogenic signaling pathways. This knowledge could clar-
ify the molecular pathogenesis and the occurrence and de-
velopment of HCC. All the above will prompt us to find
new diagnostic markers and potential methods to treat
HCC. Nevertheless, translating the research data on the
mechanistic cause of miRNA dysregulation to applications
for clinical practice will require significant work and will
be an important field for HCC study.
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